The Zhitong Finance App learned that German private biotech company Disco Pharmaceuticals said on Thursday that ABBV.US (ABBV.US) agreed to pay up to 2.54 billion US dollars to jointly develop cancer treatments with Disco, which marks the pharmaceutical company's early layout for the next generation of bispecific antibody therapy.

Zhitongcaijing · 2d ago
The Zhitong Finance App learned that German private biotech company Disco Pharmaceuticals said on Thursday that ABBV.US (ABBV.US) agreed to pay up to 2.54 billion US dollars to jointly develop cancer treatments with Disco, which marks the pharmaceutical company's early layout for the next generation of bispecific antibody therapy.